Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)-Reference-Cited by-同舟云学术

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

Published:2006-10 Issue:4 Volume:152 Page:627-635
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Wiviott Stephen D.,Antman Elliott M.,Gibson C. Michael,Montalescot Gilles,Riesmeyer Jeffrey,Weerakkody Govinda,Winters Kenneth J.,Warmke Jeffrey W.,McCabe Carolyn H.,Braunwald Eugene

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology;Patrono;Eur Heart J,2004

2. Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting

3. Bone marrow aplasia associated with ticlopidine therapy;Elias;Am J Hematol,1993

4. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study;Mehta;Lancet,2001

Cited by 283 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention;Journal of Clinical Medicine;2024-07-19

2. Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention;Pharmacogenomics;2024-05-02

3. Comprehensive comparative efficacy and safety of potent P2Y12 inhibitors in patients undergoing coronary intervention: A systematic review and meta-analysis;IJC Heart & Vasculature;2024-04

4. Pharmacogenomic Biomarkers in Coronary Artery Disease: A Narrative Review;Biomarkers in Medicine;2024-03

5. Association between body mass index and three-year outcome of acute myocardial infarction;Scientific Reports;2024-03-01